|1.||Tanihara, Hidenobu: 13 articles (06/2014 - 03/2007)|
|2.||D'Andrea, Alan D: 13 articles (12/2011 - 07/2002)|
|3.||Gedde, Steven J: 11 articles (06/2014 - 08/2005)|
|4.||Inatani, Masaru: 11 articles (06/2014 - 03/2007)|
|5.||Joenje, Hans: 10 articles (01/2012 - 02/2002)|
|6.||Cunningham, D: 9 articles (03/2015 - 04/2002)|
|7.||Lønning, Per Eystein: 9 articles (12/2014 - 11/2003)|
|8.||Cunningham, David: 9 articles (08/2014 - 07/2002)|
|9.||Inoue, Toshihiro: 9 articles (06/2014 - 03/2007)|
|10.||Schiffman, Joyce C: 9 articles (06/2014 - 08/2005)|
11/01/1988 - "Mitomycin C is effective for treatment of residual superficial tumor and when instilled regularly after complete transurethral resection (prophylaxis). "
02/01/2000 - "Phase III trials have shown that mitomycin C can be as effective as BCG in the management of papillary tumors; however, BCG is more effective in patients with CIS and high-risk superficial tumors."
02/01/1998 - "A significant reduction in the number of tumor colonies was obtained when repeated subcutaneous administrations of mitomycin C-blocked transfectant cells were given, commencing 3 days after an intravenous challenge with TSA cells. "
05/01/1988 - "In combination with JTX, mitomycin C resulted in a significantly greater tumor growth inhibition than could be obtained with mitomycin C alone. "
01/01/1985 - "Subsequent tests indicated that the ip inoculation of X-irradiated or mitomycin-treated tumor cells of low-metastatic clones elicited a significantly greater peritoneal infiltration of macrophages than did tumor cells of high-metastatic clones. "
03/01/1998 - "Adjunctive mitomycin C significantly (P < .05) improved the filtration outcome of the primary glaucoma triple procedure in the subgroups with each of the three prognostic factors for filtration failure of primary glaucoma triple procedure. "
07/01/2002 - "Mitomycin and rAd.p21 were effective in preventing fibroproliferation and wound healing in a rabbit model of glaucoma surgery. "
03/01/2000 - "In this retrospective case series with relatively short follow-ups, AGV implantation with mitomycin C in refractory glaucoma appears to be effective without increased complication rates."
10/01/2009 - "To evaluate the safety and efficacy of deep sclerectomy with implant and mitomycin C in uveitic glaucoma. "
01/01/1995 - "The authors assessed the efficacy of adjunctive intraoperative mitomycin C to produce lower intraocular pressures (IOPs) in patients with complicated glaucoma who underwent double-plate Molteno implantation. "
03/01/2010 - "Intra-operative application of 0.4mg/ml Mitomycin C is very effective in reduction of recurrence of pterygium after excision. "
05/01/2005 - "Despite the established efficacy of mitomycin C (MMC) in preventing recurrence after pterygium surgery, there is no consensus on the optimal operative technique or dose of MMC. "
05/01/2005 - "Safety and efficacy of the technique of complete tenon's membrane excision and mitomycin C in pterygium surgery."
06/01/2000 - "The intraoperative administration of 0.04% mitomycin C is more effective than beta irradiation as an adjunctive treatment for pterygium surgery in the patient population examined in this study."
09/01/2013 - "Pterygium excision using bulbar conjunctival autograft with intraoperative mitomycin C was effective in primary pterygium."
|4.||Urinary Bladder Neoplasms (Bladder Cancer)
09/01/2011 - "Bladder cancer: EMDA mitomycin before TURBT is the best treatment for non-muscle-invasive disease."
01/01/1992 - "at the dose of 50 micrograms per animal per day during 6-week period of promotion with mitomycin C, the incidence of urinary bladder cancer was dramatically reduced. "
08/01/2015 - "This study sought to determine if the addition of perioperative mitomycin C (MMC) to treatment with bacillus Calmette-Guérin (BCG) after transurethral resection (TURBT) is superior to TURBT plus BCG alone in high grade non-muscle invasive bladder cancer (NMIBC). "
03/01/2004 - "Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials."
11/01/1998 - "We study toxicity and efficacy of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin (BCG) in patients with intermediate or high risk superficial bladder cancer compared to the use of intravesical mitomycin C alone. "
01/01/1997 - "Based on a few previous studies, intra-peritoneal hyperthermic perfusion (IPHP) with Mitomycin C could become a beneficial treatment for peritoneal carcinomatosis. "
06/01/2009 - "Topical mitomycin C may be effective for treating pagetoid spread of sebaceous carcinoma of limbal origin."
04/01/2004 - "To compare the therapeutic efficacy of intravesical bacille Calmette-Guérin (BCG) with mitomycin C (MMC) on progression of Stage Ta and T1 bladder carcinoma. "
01/01/2003 - "We compare the therapeutic efficacy and toxicity of intravesical bacillus Calmette-Guerin (BCG) with mitomycin C on recurrence of stages Ta and T1 bladder carcinoma. "
11/01/2002 - "Preliminary evidence suggests that topical mitomycin-C is effective treatment for pagetoid invasion of the conjunctiva by sebaceous gland carcinoma. "
|6.||Vinblastine (Vinblastine Sulfate)
|1.||Drug Therapy (Chemotherapy)